It is unknown whether disease activity according to consensus criteria (magnetic resonance imaging activity or clinical relapses) associate with cerebrospinal fluid (CSF) changes in progressive multiple sclerosis (MS).
Objective:
To compare CSF biomarkers in active and inactive progressive MS according to consensus criteria.
Methods:
Neurofilament light chain (NFL), myelin basic protein (MBP), IgG-index, chitinase-3-like-1 (CHI3L1), matrix metalloproteinase-9 (MMP-9), chemokine CXCL13, terminal complement complex, leukocyte counts and nitric oxide metabolites were measured in primary (n = 26) and secondary progressive MS (n = 26) and healthy controls (n = 24).
Results:
Progressive MS patients had higher CSF cell counts, IgG-index, CHI3L1, MMP-9, CXCL13, NFL and MBP concentrations. Active patients were younger and had higher NFL, CXCL13 and MMP-9 concentrations than inactive patients. Patients with active disease according to consensus criteria or detectable CXCL13 or MMP-9 in CSF were defined as having combined active progressive MS. These patients had increased CSF cell counts, IgG-index and MBP, NFL and CHI3L1 concentrations. Combined inactive patients only had increased IgG-index and MBP concentrations.
Conclusion:
Patients with combined active progressive MS show evidence of inflammation, demyelination and neuronal/axonal damage, whereas the remaining patients mainly show evidence of active demyelination. This challenges the idea that neurodegeneration independent of inflammation is crucial in disease progression.
LublinFDReingoldSC.Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–911.
2.
ConfavreuxCVukusicSMoreauTet al. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–1438.
3.
ConfavreuxCVukusicSAdeleineP.Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126: 770–782.
4.
LublinFDReingoldSCCohenJAet al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
5.
Romme ChristensenJBornsenLKhademiMet al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler2013; 19: 877–884.
6.
PolmanCHReingoldSCEdanGet al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’. Ann Neurol2005; 58: 840–846.
7.
RatzerRIversenPBornsenLet al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Mult Scler2016; 22: 926–934.
8.
Romme ChristensenJRatzerRBornsenLet al. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology2014; 82: 1499–1507.
9.
Vinther-JensenTBornsenLBudtz-JorgensenEet al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm2016; 3: e287.
10.
ModvigSDegnMHorwitzHet al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE2013; 8: e77163.
11.
BrettschneiderJCzerwoniakASenelMet al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS ONE2010; 5: e11986.
12.
SellebjergFBornsenLKhademiMet al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology2009; 73: 2003–2010.
13.
SellebjergFSorensenTL.Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull2003; 61: 347–355.
14.
KhademiMDringAMGilthorpeJDet al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: A reflection by cerebrospinal fluid biomarkers. PLoS ONE2013; 8: e63172.
15.
MalmestromCHaghighiSRosengrenLet al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology2003; 61: 1720–1725.
16.
SemraYKSeidiOAShariefMK.Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol2002; 122: 132–139.
17.
EdwardsKRGoyalJPlavinaTet al. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS ONE2013; 8: e81007.
18.
CorrealeJFiolM.Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler2011; 17: 521–531.
19.
BurmanJRaininkoRBlennowKet al. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol2016; 292: 52–57.
20.
MalmestromCAxelssonMLyckeJet al. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol2014; 269: 87–89.
21.
ModvigSDegnMSanderBet al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler2016; 22: 590–598.
22.
ModvigSDegnMRoedHet al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler2015; 21: 1761–1770.
23.
NorgrenNSundstromPSvenningssonAet al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology2004; 63: 1586–1590.
24.
SalzerJSvenningssonASundstromP.Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler2010; 16: 287–292.
25.
TrentiniAComabellaMTintoreMet al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol2014; 261: 2338–2343.
26.
AxelssonMMalmestromCGunnarssonMet al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler2014; 20: 43–50.
27.
GunnarssonMMalmestromCAxelssonMet al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol2011; 69: 83–89.
CohenSRHerndonRMMcKhannGM.Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination. N Engl J Med1976; 295: 1455–1457.
30.
ThompsonAJHutchinsonMBrazilJet al. A clinical and laboratory study of benign multiple sclerosis. Q J Med1986; 58: 69–80.
31.
ThompsonAJBrazilJHutchinsonMet al. Three possible laboratory indexes of disease activity in multiple sclerosis. Neurology1987; 37: 515–519.
32.
SellebjergFChristiansenMJensenJet al. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol2000; 7: 281–289.
33.
SellebjergFJensenCVChristiansenM.Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis. J Neuroimmunol2000; 108: 207–215.
34.
LamersKJUitdehaagBMHommesORet al. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry1988; 51: 1334–1337.
RejdakKEikelenboomMJPetzoldAet al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology2004; 63: 1439–1445.
37.
SellebjergFJaliashviliIChristiansenMet al. Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci1998; 157: 168–174.
38.
StysPKZamponiGWVanMJet al. Will the real multiple sclerosis please stand up?Nat Rev Neurosci2012; 13: 507–514.
39.
MahadDHTrappBDLassmannH.Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol2015; 14: 183–193.
